CSYS yields 200000000.00% · ABBV yields 3.12%● Live data
📍 CSYS pulled ahead of the other in Year 1
Combined, CSYS + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CSYS + ABBV for your $10,000?
ClearStory Systems, Inc. develops digital asset management (DAM) and enterprise content management software solutions. The company offers Radiant Enterprise Media Server (RADIANT EMS), a J2EE platform for document and media solutions; ActiveMedia, an enterprise DAM application that is built on Radiant EMS platform, which offers a secure central repository where rich media files, such as images, documents, video, animation, and voice formats of media and brand assets are organized and stored; Radiant Business Document Server, a system for document capture, archiving, and online presentment; and Radiant Mailmanager, an email archiving solution that provides lifecycle, compliance, and storage management for the corporate email knowledge. It also provides standards based technology solution, a platform for integrating media and business documents into various business environments, such as marketing and finance departments, call centers, channel partner portals, compliance initiatives, and marketing extranets. The company serves media and entertainment, pharmaceutical, consumer packaged goods, financial services, and healthcare industries. ClearStory Systems, Inc. was formerly known as INSCI Corp. and changed its name to ClearStory Systems, Inc. in December 2001. The company was founded in 1989. The company is based in Westborough, Massachusetts. ClearStory Systems, Inc. operates as a subsidiary of Piksel, Inc.
Full CSYS Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.